Monoclonal antibodies targeting IL-33, such as tozorakimab and itepekimab, are currently in clinical trials for chronic obstructive pulmonary disease (NCT05166889 and NCT05158387), asthma (NCT04570657), and acute respiratory failure (NCT05624450) and might be repurposed for PAH. This evidence concerns the gene IL33 and respiratory failure.